Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Joan Whitten Miller, M.D.

Co-Author

This page shows the publications co-authored by Joan Miller and Anthony Adamis.
Connection Strength

1.315
  1. Judah Folkman. Semin Ophthalmol. 2009 May-Jun; 24(3):128-9.
    View in: PubMed
    Score: 0.407
  2. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996 Jan; 114(1):66-71.
    View in: PubMed
    Score: 0.161
  3. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003 Aug 04; 198(3):483-9.
    View in: PubMed
    Score: 0.068
  4. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):290-9.
    View in: PubMed
    Score: 0.066
  5. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar; 120(3):338-46.
    View in: PubMed
    Score: 0.062
  6. Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am. 2002 Mar; 15(1):87-91.
    View in: PubMed
    Score: 0.062
  7. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1181-5.
    View in: PubMed
    Score: 0.054
  8. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1186-91.
    View in: PubMed
    Score: 0.054
  9. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000 Jan; 118(1):78-84.
    View in: PubMed
    Score: 0.053
  10. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999 Aug; 40(9):2115-21.
    View in: PubMed
    Score: 0.052
  11. Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol. 1997 Dec; 115(12):1553-8.
    View in: PubMed
    Score: 0.046
  12. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997 Mar; 13(1):37-50.
    View in: PubMed
    Score: 0.044
  13. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996 Nov; 103(11):1820-8.
    View in: PubMed
    Score: 0.043
  14. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996 Aug; 114(8):964-70.
    View in: PubMed
    Score: 0.042
  15. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994 Oct 15; 118(4):445-50.
    View in: PubMed
    Score: 0.037
  16. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep; 145(3):574-84.
    View in: PubMed
    Score: 0.037
  17. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jun; 44(6):2743-9.
    View in: PubMed
    Score: 0.017
  18. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci. 1996 Jun; 37(7):1334-40.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.